Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer  There were low rates of adverse events attributed to unconjugated payload such as hematological toxicities and diarrhea, and there were no cases of interstitial lung disease, showing a differentiated safety profile of BHV-1510 from other Trop2 ADCs BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates encouraging early clinical activity and favorable safety profile in a Phase 1 study in combination with the anti-PD-1 cemiplimab LONDON and NEW HAVEN, Conn. , Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Dec 11, 2025

How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52%

The average of price targets set by Wall Street analysts indicates a potential upside of 127.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Dec 4, 2025

Biohaven Insiders Bet $33 Million on a Turnaround

When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.

MarketBeat • Nov 20, 2025

Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?

On November 17, 2025, Biohaven's Chief Accounting Officer, George Clark, acquired 17,000 shares of company stock. Mr. Clark's purchase was valued at approximately $144,800.

The Motley Fool • Nov 19, 2025

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Nov 13, 2025

Biohaven Q3 Earnings: Falling Back To Earth With A Thud

Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depression and epilepsy, TRAP/MoDE degraders for IgA nephropathy and Graves' disease, and Taldefgrobep alfa for obesity and spinal muscular atrophy. Despite intriguing science and large market opportunities, clinical progress has been slow, with limited compelling data and stiff competition in target indications.

Seeking Alpha • Nov 12, 2025

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Nov 12, 2025

FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday.

Benzinga • Nov 12, 2025

Biohaven Announces Proposed Public Offering of Common Shares

NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Nov 11, 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire • Nov 10, 2025